Calmer Co Launches Discounted Entitlement Offer to Raise $2.2M

About Calmer Co International Limited

Calmer Co International Limited (ASX: CCO), founded in 2014 and headquartered in Brisbane, Queensland, is a health and wellness company specialising in natural, plant-based products for relaxation, sleep, and mental wellbeing. The company’s product portfolio includes functional beverages, kava powders, teas, capsules, and hemp-based extracts sold under brands such as Fiji Kava, Taki Mai, and Danodan Hempworks. It operates across Australia, the United States, China, New Zealand, and Fiji, and also distributes Leilo kava drinks in the Pacific region. The Calmer Co’s shares are currently trading at $0.005.

Details of the Entitlement Offer

The offer provides eligible shareholders the opportunity to acquire 2 new shares for every 7 existing shares held at an issue price of $0.003 per share. Each two new shares subscribed for will also include one free attaching option (ASX: CCOOA), exercisable at $0.006 and expiring on 30 June 2026. The structure offers a discounted entry price and long-dated option upside, designed to reward existing shareholders and attract new participation.

If fully subscribed, the company will issue up to 729.7 million new shares and 364.8 million options, raising approximately $2.2 million before costs. The offer is renounceable, allowing shareholders to trade their rights on the ASX if they choose not to participate directly. A top-up facility will also allow shareholders who fully take up their entitlements to apply for additional shortfall shares.

Mahe Capital Pty Ltd is acting as lead manager and underwriter for the raise and will receive 44 million options as part of its fee structure. The record date for eligibility is 22 April 2025, with the offer opening on 24 April and closing on 9 May 2025. Shares and options issued under the offer are expected to begin trading on the ASX from 19 May 2025.

Use of Funds and Strategic Growth Plan

Funds raised from the entitlement offer will be used to expand inventory to meet rising sales demand and prepare for entry into new markets, particularly in North America and Asia. A portion of the capital will also support upgrades to manufacturing equipment at the company’s Navua Facility in Fiji, enhancing production capacity and efficiency. Additionally, proceeds will fund the execution of e-commerce and brand awareness campaigns in Australia and the United States, aimed at boosting online sales and strengthening consumer engagement. The company also plans to launch new wellness products aligned with global trends in natural stress relief. Remaining funds will be applied toward general working capital requirements, including operational costs and expenses associated with the offer.

Outlook and Shareholder Opportunity

The entitlement offer is a pivotal component of The Calmer Co’s strategy to scale up production and broaden its global reach in the wellness market. The company is capitalising on growing consumer interest in natural, non-pharmaceutical remedies for stress, sleep disorders, and mental wellbeing. With strong brand positioning and a vertically integrated supply chain anchored in Fiji, the business is targeting improved profit margins and international expansion.

Shareholders who participate in the offer will gain exposure at a significant discount to the market price, with the added benefit of long-dated, low-exercise-price options. The board has encouraged eligible shareholders to review the offer documents in detail and consider participating as the company prepares for a new phase of growth.

The outcome of the entitlement offer will be closely watched by investors as The Calmer Co seeks to strengthen its balance sheet and accelerate its transition toward a more globally competitive wellness business.